Judicial Watch: Records Show U.S. and UK ‘Confidentiality Agreement’ Tied to Vaccine Adverse Events

Judicial Watch is a great resource of information on the covid scam. I reviewed many of their FOIA productions and published articles based on the information obtained. Here is an article by Bill Marshall, a journalist at JW. Highly relevant to demonstrating the international collusion by the US and UK regulators.

(Washington, DC) – Judicial Watch announced today it received 57 pages of heavily redacted records from the U.S. Department of Health and Human Services (HHS) that show, just two days prior to FDA approval of the Pfizer-BioNTech COVID-19 vaccine, a discussion between U.S. and UK health regulators regarding the COVID shot and “anaphylaxis” with the regulators emphasizing their “mutual confidentiality agreement.”

Judicial Watch obtained the records through a Freedom of Information Act (FOIA) lawsuit against HHS (Judicial Watch v. U.S. Department of Health and Human Services (No. 1:22-cv-00660)) after the Food and Drug Administration (FDA), which is an agency of HHS, failed to respond to an August 30, 2021, FOIA request for:

All emails sent to and from members of the Vaccines and Related Biological Products Advisory Committee regarding adverse events, deaths and/or injuries caused by investigatory vaccines for the prevention or treatment of SARS-CoV-2 and/or COVID-19 currently produced by Pfizer/BioNTech, Moderna and/or Johnson & Johnson.

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) is the U.S. Government’s central advisory body, along with Advisory Committee on Immunization Practices (ACIP), advising whether to approve COVID vaccines.

A lengthy, heavily redacted December 2020 email exchange shows U.S. and UK health officials placing a heavy emphasis on their “mutual confidentiality agreement” in a discussion regarding “anaphylactoid reactions” to the COVID vaccine.

The exchange is initiated by Jonathan Mogford, policy director of the UK’s Medicines and Healthcare Products Regulatory Agency and is sent to Acting FDA Commissioner Janet Woodcock as well as Peter Marks, director of the Center for Biologics Evaluation and Research (CBER). The subject line and body of the email are fully redacted under FOIA Exemption B3 (relating to statutory prohibitions).

As background, Mogford includes information on “two cases of anaphylactoid reactions in individuals with a strong past history of allergic reactions….” Marks replies to Mogford: “It would be very helpful if our Office of Vaccines could receive additional details [redacted] from MHRA [UK Medicines and Healthcare Products Regulatory Agency] under the terms of our mutual confidentiality agreement.” Mogford later replies, “… attached are [redacted] hope that’s helpful in the meantime. If I can just remind – information shared under our confidentiality agreement.”

Marion Gruber, head of the Office of Vaccines Research and Review (OVRR), then replies to Mogford, “Thank you so much for this information. Our emails crossed. If possible, would be available for a t-con [teleconference] today?” The exchange concludes with OVRR Deputy Director Phil Krause advising UK Medicines and Healthcare Products Regulatory Agency official Jamie Convisser, “Your summary is correct. I’m cc:ing Amanda Cohn at CDC who can provide the most up-to-date details about [redacted]. Obviously, [redacted], not all of this is public so please hold these details confidential.” Cohn then replies to Mogford, and includes an attachment titled “Anaphylaxis CLARK Dec 19 2020 Final”. She writes, “I am adding my colleagues Tom Clark and Stacey Martin, we are happy to share more information with you. Attached are slides that were presented at a public meeting on Saturday. [Redacted].”

The FDA issued its Emergency Use Authorization for the Pfizer-BioNTech COVID vaccine for individuals 16 years of age and older on December 11, 2020.

On May 14, 2021, the CDC’s Dr. Amanda Cohn emailed Office of Vaccines Research and Review Director Marion Gruber and Center for Biologics Evaluation and Research Director Peter Marks with the subject line “Coadministration of COVID-19 Vaccines with Other Vaccines During Pregnancy.”

Gruber writes, “I am fine with this language.” Marks then responds to Cohn and her CDC colleague, Sarah Mbaeyi, “I can live with this too. Please let me know if you want to connect about the adverse event issue later today. Seems like work is still ongoing, but let me know. Thanks.” Cohn replies, “We have a meeting with Rochelle [presumably CDC Director Rochelle Walensky] at 3:30 about if we should say anything or wait until we have more definitive information. I will let you know where we land. I’m not sure there is a right answer.”



You’ll find the source for all of of Dr Ardis’ suggested supplements right below. You’ll find this video LIFE SAVING. Finally, someone who did the research, tested it, and came up with the solution.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s